Retrospective case note review of chronic spontaneous urticaria outcomes and adverse effects in patients treated with omalizumab or ciclosporin in UK secondary care

BACKGROUND: Omalizumab is approved in the UK as add-on treatment for chronic spontaneous urticaria (CSU) in patients with inadequate response to H(1)-antihistamines. Ciclosporin is an established but unlicensed 3rd line option for CSU. Two parallel retrospective observational studies were conducted...

Descripción completa

Detalles Bibliográficos
Autores principales: Savic, Sinisa, Marsland, Alexander, McKay, David, Ardern-Jones, Michael R, Leslie, Tabi, Somenzi, Olivier, Baldock, Laura, Grattan, Clive
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4507325/
https://www.ncbi.nlm.nih.gov/pubmed/26195984
http://dx.doi.org/10.1186/s13223-015-0088-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4507325/
https://www.ncbi.nlm.nih.gov/pubmed/26195984
http://dx.doi.org/10.1186/s13223-015-0088-7

Ejemplares similares